RxDoctor Payments Data

Shelley Hall, MD

Advanced Heart Failure and Transplant Cardiology · Dallas, TXNPI 1912961145

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $157,730 of the $253,895 with a category attached, or 62.1%. 21 manufacturers reported payments, led by Abbott at 50.6% of the total. 2025 is the largest year on record at $92,741, 3.1 times the $29,826 reported in 2019. Among advanced heart failure and transplant cardiology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$253,895in general payments, 2019–2025

Across 372 payments — averaging $682.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$128K
  • Cvrx, Inc.$49K
  • Abiomed$32K
  • Novartis$25K
  • Medtronic$11K
  • Sanofi-aventis U.S. LLC$7K
  • plus $1K from 15 others
$1,060,054in research payments, 2019–2025

Across 166 payments — averaging $6385.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$703K
  • Novartis$183K
  • American Regent$70K
  • Veloxis Pharmaceuticals, Inc.$59K
  • Actelion Pharmaceuticals, Ltd$30K
  • Sanofi US Services Inc.$16K

What the payments were for

  • Consulting fees$157,73062%
  • Speaking & faculty fees$57,83123%
  • Grants$7500%
  • Travel & lodging$22,9329%
  • Food & beverage$14,6536%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$253,895 in reported general payments places this provider in the 90th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.

See all advanced heart failure and transplant cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$57,907
Medicare patients
169
Services billed
639

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan32$39,471
EliquisApixaban12$18,673
Sirolimus39$8,995
Cyclosporine ModifiedCyclosporine, Modified21$8,224
Tacrolimus77$5,170
Mycophenolate Mofetil36$2,424
Torsemide23$530
Ezetimibe28$500
Rosuvastatin Calcium35$484
Fluconazole12$405
Metoprolol Succinate21$397
Spironolactone33$347
Atorvastatin Calcium36$338
Prednisone35$312
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim48$282

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$24,769$39,47132 claims
PfizerEliquis$16$18,67312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.

Other advanced heart failure and transplant cardiology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →